BackIN8bio Overview

IN8bio Long Term Debt

Track IN8bio's long-term debt ($1.3M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$1.33M
↓ 56.31% YoYΔ $-1.71M vs prior year quarter

Peer average

Loading

IN8bio Long Term Debt History

Loading

IN8bio vs. peers: Long Term Debt Comparison

Loading

IN8bio Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

IN8bio (INAB) FAQ

As of the most recent data (March 2026), INAB shows a long-term debt of $1.3M. That compares with $3M in the prior-year period — down 56.3% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, INAB's long-term debt is now $1.3M (was $3M) — a 56.3% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether IN8bio is outperforming or lagging.

Tracking INAB's long-term debt over time shows whether IN8bio is scaling, shrinking, or reshaping that part of the business. The current reading is $1.3M That compares with $3M in the prior-year period — down 56.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has IN8bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $1.3M) with ownership activity and broader fundamentals.

IN8bio's long-term debt is $1.3M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.